Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Meloxicam and 5′-Carboxymeloxicam in Oral Fluid Samples

A sensitive, selective and particularly fast method of liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for the determination of meloxicam and its main metabolite, 5′-carboxymeloxicam, in oral fluid samples. Meloxicam and its major metabolite were separated using a Shim-Pack XR-ODS 75 L × 2.0 column and C18 pre-column at 40 °C using a mixture of methanol and 10 mM ammonium acetate (80:20, v/v) with an injection flow rate of 0.3 mL/min. The total time of the analytical run was 5 min. Sixteen volunteers had oral fluid samples collected sequentially before and after taking a meloxicam tablet (15 mg) for up to 96 h. With the concentrations obtained, the pharmacokinetic parameters were determined using the Phoenix WinNonlin software. The parameters evaluated for meloxicam and 5′-carboxymeloxicam in the oral fluid samples showed linearity, accuracy, precision, medium-quality control (MQC-78.12 ng/mL), high-quality control (HQC-156.25 ng/mL), lower limits of quantification (LLOQ-0.6103 ng/mL), low-quality control (LQC-2.44 ng/mL), stability and dilution. Prostaglandin E2 (PGE2) was also detected and quantified in the oral fluid samples, demonstrating the possibility of a pharmacokinetic/pharmacodynamic (PK/PD) study with this methodology. All the parameters evaluated in the validation of the methodology in the oral fluid samples proved to be stable and within the possible variations in each of the described parameters. Through the data presented, the possibility of a PK/PD study was demonstrated, detecting and quantifying meloxicam, its main metabolite and PGE2 in oral fluid samples using LC-MS/MS.

[1]  T. J. Dionísio,et al.  Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazol—Results , 2022, PloS one.

[2]  T. J. Dionísio,et al.  CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid , 2022, Metabolites.

[3]  T. J. Dionísio,et al.  Detection and quantification of prostaglandin E2 in saliva by liquid chromatography-tandem mass spectrometry using microextraction by packed sorbent. , 2022, Prostaglandins & other lipid mediators.

[4]  A. M. Calvo,et al.  Analysis of Different Methods of Extracting NSAIDs in Biological Fluid Samples for LC-MS/MS Assays: Scoping Review , 2022, Metabolites.

[5]  C. Jang,et al.  Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes , 2021, Archives of Pharmacal Research.

[6]  Rongfeng Hu,et al.  Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. , 2021, Biomedical chromatography : BMC.

[7]  M. Whirl‐Carrillo,et al.  An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine , 2021, Clinical pharmacology and therapeutics.

[8]  C. Jang,et al.  Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism , 2021, Archives of Pharmacal Research.

[9]  T. J. Dionísio,et al.  Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography–tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole , 2020, PloS one.

[10]  S. Armenta,et al.  Determination of Third Generation Synthetic Cannabinoids in Oral Fluids. , 2020, Journal of analytical toxicology.

[11]  Huixi Zou,et al.  Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges , 2020, Frontiers in Pharmacology.

[12]  R. Lucena,et al.  Microextraction approaches for bioanalytical applications: An overview. , 2019, Journal of chromatography. A.

[13]  Shemille A. Collingwood,et al.  Meloxicam in the management of post-operative pain: Narrative review , 2018, Journal of anaesthesiology, clinical pharmacology.

[14]  Dongmei Li,et al.  Facile derivatization of ultratrace carboxylic acids in saliva for quantification by HPLC–MS/MS , 2018, Analytical and Bioanalytical Chemistry.

[15]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[16]  V. Samanidou,et al.  Green approaches in sample preparation of bioanalytical samples prior to chromatographic analysis. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  Sook-Joung Lee,et al.  Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen , 2017, Drug design, development and therapy.

[18]  Xiaomei Zhuang,et al.  PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.

[19]  V. Lanchote,et al.  Effective method for the detection of piroxicam in human plasma using HPLC. , 2016, Brazilian oral research.

[20]  K. Srisailam,et al.  Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies , 2016, SpringerPlus.

[21]  M. H. Fernandes,et al.  Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. , 2016, Journal of pharmaceutical and biomedical analysis.

[22]  B. Grung,et al.  Development and validation of an extraction method for the determination of pro-inflammatory eicosanoids in human plasma using liquid chromatography-tandem mass spectrometry. , 2014, Journal of chromatography. A.

[23]  J. Katz COX-2 inhibition: what we learned--a controversial update on safety data. , 2013, Pain medicine.

[24]  M. Abdel-Rehim,et al.  Screening and determination of drugs in human saliva utilizing microextraction by packed sorbent and liquid chromatography-tandem mass spectrometry. , 2013, Biomedical chromatography : BMC.

[25]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[26]  T. Arafat,et al.  Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. , 2012, Molecular pharmaceutics.

[27]  T. Toyo’oka,et al.  Simple and practical derivatization procedure for enhanced detection of carboxylic acids in liquid chromatography-electrospray ionization-tandem mass spectrometry. , 2010, Journal of pharmaceutical and biomedical analysis.

[28]  V. Rollason,et al.  Pharmacogenetics of analgesics: toward the individualization of prescription. , 2008, Pharmacogenomics.

[29]  C. Jang,et al.  Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  Xiaoyan Chen,et al.  Determination of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry following transdermal administration. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  R. Moreno,et al.  Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. , 2006, International journal of clinical pharmacology and therapeutics.

[32]  L. Blomberg,et al.  Microextraction in packed syringe (MEPS) for liquid and gas chromatographic applications. Part II--Determination of ropivacaine and its metabolites in human plasma samples using MEPS with liquid chromatography/tandem mass spectrometry. , 2004, Journal of mass spectrometry : JMS.

[33]  E. Rondinelli,et al.  CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians , 2004, Clinical pharmacology and therapeutics.

[34]  T. Ebner,et al.  Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[36]  D. Türck,et al.  A review of the clinical pharmacokinetics of meloxicam. , 1996, British journal of rheumatology.

[37]  C. Dollery,et al.  Drug concentration in saliva , 1978, Clinical pharmacology and therapeutics.

[38]  K. Feller,et al.  On the distribution of drugs in saliva and blood plasma. , 1977, International journal of clinical pharmacology and biopharmacy.

[39]  P Kellaway,et al.  Use of saliva in therapeutic drug monitoring. , 1977, Clinical chemistry.

[40]  M. H. Fernandes,et al.  Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. , 2021, Brazilian dental journal.

[41]  T. Schmidt,et al.  Solvent-free microextraction techniques in gas chromatography , 2011, Analytical and Bioanalytical Chemistry.

[42]  A. S. Trindade,et al.  Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. , 2007, International journal of oral and maxillofacial surgery.

[43]  A. Guillouzo,et al.  Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.